

ALLERGY / IMMUNOLOGY INFUSION ORDERS

P: 888-386-0886 | F: 586-263-3306

| PATIENT INFORMATI | ON: Fax completed form, insurance information and clinical documentation to | 586-263-3306 |
|---|---|---------------------------|
| Patient Name: | DOB: Phone: | |
| Last 4 of SS #: | Patient Status: New Continuing Therapy Next Treatment D | ate: |
| MEDICAL INFORMAT | ION: | |
| Patient weight: | bs. Allergies: | |
| THERAPY ORDER | | |
| Diagnosis | Infusion Orders | Refills |
| ☐ Common Variable Immunodeficiency (ICD-10 Code:) ☐ Other: (ICD-10 Code:) | Immunoglobullin: □ IV □ SubQ mg/kg OR gm/kg x day(s) OR divided over day(s) Frequency: Every weeks OR (Compassus to choose if not indicated) Brand: Additional lg orders: | □ □ x1year |
| | Solu-Medrol mg IVP | |
| | | |
| PROVIDER INFORMA | | sted agost in dealther. W |
| By signing this form and utilizing our services medical and prescription insurance companie | you are authorizing <i>Compassus</i> and its employees to serve as your prior authorization and specialty pharmacy designs, and to select the preferred site of care for the patient. | |
| By signing this form and utilizing our services medical and prescription insurance companie Patient Name: | you are authorizing <i>Compassus</i> and its employees to serve as your prior authorization and specialty pharmacy designs, and to select the preferred site of care for the patient. Signature: Date: | |
| By signing this form and utilizing our services medical and prescription insurance companie Patient Name: Provider NPI: | you are authorizing Compassus and its employees to serve as your prior authorization and specialty pharmacy designs, and to select the preferred site of care for the patient. Signature: Date: Phone: Fax: Contact Person: | : |
| By signing this form and utilizing our services medical and prescription insurance companie Patient Name: Provider NPI: | you are authorizing <i>Compassus</i> and its employees to serve as your prior authorization and specialty pharmacy designs, and to select the preferred site of care for the patient. Signature: Date: | : |
| By signing this form and utilizing our services medical and prescription insurance companie Patient Name: Provider NPI: | you are authorizing Compassus and its employees to serve as your prior authorization and specialty pharmacy designs, and to select the preferred site of care for the patient. Signature: Phone: Fax: Contact Person: ing site of care (if checked, please list site of care): | · |



☐ Xolair - Patient has Epi pen prescribed

Other medical necessity:

COMPREHENSIVE SUPPORT FOR ALLERGY / IMMUNOLOGY THERAPY P: 888-386-0886 | F: 586-263-3306

PATIENT INFORMATION: Fax completed form, insurance information and clinical documentation to 586-263-3306 Patient Name: DOB: REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING AND INSURANCE APPROVAL ☐ Include signed and completed order (MD/prescriber to complete page 1) ☐ Include patient demographic information and insurance information ☐ Include patient's medication list ☐ Supporting clinical notes to include any past tried and/or failed therapies, intolerance, benefits, or contraindications to conventional therapy ☐ Please indicate any tried and failed therapies (if applicable): □ Corticosteroids _____ □ Long acting beta 2 agonist _____ ☐ Long acting muscarinic antagonist _____ ☐ Immunosuppressants (EGPA) _____ ☐ Asthma - Does the patient have a history of 2 exacerbations requiring a course of oral/systemic corticosteroids, hospitalization or an emergency room visit with a 12-month period? ☐ Yes ☐ No □ Asthma - Does the patient have a ACQ score consistently greater than 1.5 or ACT sore consistently less than 120 □ Yes □ No ☐ PI- Documentation of recurrent bacterial infections, history of failure to respond to antibiotics, documentation of pre and post pneumococcal vaccine titer. Failure to respond to two vaccines or pneumococcal vaccine. ☐ Include labs and/or test results to support diagnosis (attach results) □ Does patient have a baseline peripheral blood eosinophil level of \geq 150 cells/mcL within the past 6 weeks (asthma & EGPA or \geq 1000 cellsmcL within 4 weeks (HES)? ☐ Yes ☐ No ☐ FEV1 score (if applicable): _____ ☐ Serum IgE level - for asthma & nasal polyps Xolair ☐ Skin/RAST test - for asthma Xolair ☐ Serum immunoglobulins - for lg ☐ Serum creatinine - for Ig ☐ CBC w/ differeential - for Fasenra, Nucala, Cinqair ☐ If injection order, is the patient or caregiver not competent or physically unable to administer the *product for self-administration?* ☐ Yes ☐ No

Compassus will complete insurance verification and submit all the required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if an additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.